Tracey Lodie joined Gamida Cell’s leadership team in June 2019, bringing over 16 years of drug discovery experience in the areas of autoimmunity, transplant biology and immuno-oncology. Previously, she served as senior vice president, translational immunology at BlueRock Therapeutics, helping to advance the company’s universal pluripotent stem cell platform into central nervous system, cardiovascular and autoimmune therapeutic areas. She also served as vice president of immunology at Syros Pharmaceuticals, where she developed new autoimmunity and immuno-oncology research programs. Prior to Syros, Tracey spent over 14 years at Sanofi-Genzyme, where she held roles of increasing responsibility. While at Sanofi-Genzyme, Tracey served as head of the immune-mediated research group and was responsible for building and advancing the early drug pipeline, integrating advanced programs into development, and supporting translational medicine for existing clinical drugs. She was instrumental in advancing several development programs through regulatory approval in the area of transplant and autoimmunity. Her work directly supported the clinical development and approval of an advanced stem cell therapy product for the treatment of GvHD. Additional chemokine biology research led to the approval of Mozobil® (plerixafor), a small molecule CXCR4 antagonist for stem cell mobilization in patients undergoing an autologous stem cell transplant for non-Hodgkin lymphoma and multiple myeloma. Additionally, Tracey’s group was responsible for data in animal models of multiple sclerosis and secondary autoimmunity that supported the approval and post-approval safety requirements of Lemtrada® (alemtuzumab), a monoclonal, anti-CD52 antibody, for relapsing remitting multiple sclerosis.
Tracey holds a Ph.D. in immunology and pathology from Boston University School of Medicine and a B.S. in biology from Fairfield University.